Molecular Partners AG's total inventories for the quarter that ended in Mar. 2026 was CHF0.00 Mil. Molecular Partners AG's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was CHF0.00 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Molecular Partners AG's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was CHF1.63.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Molecular Partners AG (XSWX:MOLN) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Molecular Partners AG's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Molecular Partners AG's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Molecular Partners AG Total Inventories Related Terms
Molecular Partners AG Total Inventories Historical Data
* Premium members only.
The historical data trend for Molecular Partners AG's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
What does a Total Inventories of CHF0.00 Mil mean?
Molecular Partners AG (XSWX:MOLN) has a Total Inventories of CHF0.00 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Molecular Partners AG and its competitors.
Is Molecular Partners AG's Total Inventories too high?
Molecular Partners AG's current Total Inventories is CHF0.00 Mil. Overall, Molecular Partners AG has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Total Inventories compare to VRTX and REGN?
Molecular Partners AG's Total Inventories of CHF0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Molecular Partners AG and its competitors. Molecular Partners AG's current Total Inventories is CHF0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (XSWX:MOLN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF0.37, compared to a current price of CHF3.12 — trading 743.2% above its estimated fair value. The current Total Inventories is CHF0.00 Mil. Molecular Partners AG's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Molecular Partners AG (XSWX:MOLN), the current Total Inventories is CHF0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Molecular Partners AG (XSWX:MOLN) Overvalued in 2026?
Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued.
The current stock price of CHF3.12 is trading 743.2% above its estimated GF Value™ of CHF0.37.
GuruFocus considers Molecular Partners AG to be Significantly Overvalued.
Key valuation signals for XSWX:MOLN:
Total Inventories: CHF0.00 Mil
GF Value™: CHF0.37 vs. price of CHF3.12 (743.2% above fair value)
No single metric tells the full story. See the XSWX:MOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
29GF Score
Get the complete analysis for XSWX:MOLN
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MOLN has been successfully added to your 
